During the past decade, Emavundleni CRS conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 7 clinical trials were completed, i.e. on average, 46.7% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 6 clinical trials were completed. i.e. 75% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Emavundleni CRS" #1 sponsor was "National Institute of Allergy and Infectious Diseases (NIAID)" with 9 trials, followed by "HIV Vaccine Trials Network" with 4 trials sponsored, "HIV Prevention Trials Network" with 2 trials sponsored, "Wits Health Consortium (Pty) Ltd" with 2 trials sponsored and "COVID-19 Prevention Network" with 2 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Emavundleni CRS" #1 collaborator was "National Institute of Allergy and Infectious Diseases (NIAID)" with 5 trials as a collaborator, "HIV Vaccine Trials Network" with 4 trials as a collaborator, "GlaxoSmithKline" with 3 trials as a collaborator, "Bill and Melinda Gates Foundation" with 2 trials as a collaborator and "Bio Analytical Research Corporation" with 2 trials as a collaborator. Other collaborators include 44 different institutions and companies that were collaborators in the rest 42 trials.

According to Clinical.Site data, the most researched conditions in "Emavundleni CRS" are "HIV Infections" (13 trials), "COVID-19" (2 trials), "HIV" (2 trials), "HIV Infection" (2 trials) and "Contraception" (1 trials). Many other conditions were trialed in "Emavundleni CRS" in a lesser frequency.

Most popular intervention types in "Emavundleni CRS" are "Biological" (13 trials), "Drug" (7 trials), "Other" (4 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "ALVAC-HIV" (2 trials), "ALVAC-HIV (vCP2438)" (2 trials), "Bivalent Subtype C gp120/MF59" (2 trials) and "AIDSVAX B/E" (1 trials). Other intervention names were less common.

The vast majority of trials in "Emavundleni CRS" are 16 trials for "All" genders and 5 trials for "Female" genders.

Currently, there are NaN active trials in "Emavundleni CRS". 1 are not yet recruiting, 2 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Emavundleni CRS, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Emavundleni CRS, 8 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".